ClindaCure

Name: ClindaCure

Manufacturer

  • Vedco, Inc.

ClindaCure Drug Class

ClindaCure is part of the drug classes:

  • Gynecological Antibiotics

  • Antiinfectives for treatment of acne

  • Lincosamides

Side Effects of ClindaCure

Serious side effects have been reported with clindamycin. See the “Clindamycin Precautions” section.

Oral:

Common side effects of oral clindamycin include the following:

  • Abdominal pain
  • Nausea
  • Vomiting
  • Diarrhea
  • Rash
  • Hives

Topical:

Common side effects of topical clindamycin include the following:

  • Burning, itching, dryness, or redness at site of application

Injectable:

Common side effects of oral clindamycin include the following:

  • Abdominal pain
  • Nausea
  • Vomiting
  • Diarrhea
  • Rash
  • Hives

This is not a complete list of clindamycin side effects. Ask your doctor or pharmacist for more information.

Tell your doctor if you have any side effect that bothers you or that does not go away.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

 

ClindaCure and Lactation

Tell your doctor if you are breastfeeding or plan to breastfeed.

Clindamycin has been detected in human breast milk. Because of the possibility for adverse reactions in nursing infants from clindamycin, a choice should be made whether to stop nursing or to stop use of this medication. The importance of the drug to the mother should be considered.

Pharmacology

Absorption

Clindamycin hydrochloride is rapidly absorbed from the canine and feline gastrointestinal tract.

Dog Serum Levels

Serum levels at or above 0.5 μg/mL can be maintained by oral dosing at a rate of 2.5 mg/lb of clindamycin hydrochloride every 12 hours. This same study revealed that average peak serum concentrations of clindamycin occur 1 hour and 15 minutes after oral dosing. The elimination half-life for clindamycin in dog serum was approximately 5 hours. There was no bioactivity accumulation after a regimen of multiple oral doses in healthy dogs.

Clindamycin Serum Concentrations 2.5 mg/lb (5.5 mg/kg) After B.I.D. Oral Dose of Clindamycin Hydrochloride to Dogs

Cat Serum Levels

Serum levels at or above 0.5 μg/mL can be maintained by oral dosing at a rate of 5 mg/lb of clindamycin hydrochloride liquid every 24 hours. The average peak serum concentration of clindamycin occurs approximately 1 hour after oral dosing. The elimination half-life of clindamycin in feline serum is approximately 7.5 hours. In healthy cats, minimal accumulation occurs after multiple oral doses of clindamycin hydrochloride, and steady-state should be achieved by the third dose.

Clindamycin Serum Concentrations 5 mg/lb (11 mg/kg) After Single Oral Dose of ClindaCure to Cats

METABOLISM AND EXCRETION

Extensive studies of the metabolism and excretion of clindamycin hydrochloride administered orally in animals and humans have shown that unchanged drug and bioactive and bioinactive metabolites are excreted in urine and feces. Almost all of the bioactivity detected in serum after clindamycin hydrochloride administration is due to the parent molecule (clindamycin). Urine bioactivity, however, reflects a mixture of clindamycin and active metabolites, especially N-dimethyl clindamycin and clindamycin sulfoxide.

Animal safety summary

Rat and Dog Data

One year oral toxicity studies in rats and dogs at doses of 30, 100 and 300 mg/kg/day (13.6, 45.5 and 136.4 mg/lb/day) have shown clindamycin hydrochloride capsules to be well tolerated.

Differences did not occur in the parameters evaluated to assess toxicity when comparing groups of treated animals with contemporary controls. Rats administered clindamycin hydrochloride 600 mg/kg/day (272.7 mg/lb/day) for six months tolerated the drug well; however, dogs orally dosed at 600 mg/kg/day (272.7 mg/lb/day) vomited, had anorexia, and subsequently lost weight. At necropsy these dogs had erosive gastritis and focal areas of necrosis of the mucosa of the gall bladder.

Safety in gestating bitches or breeding males has not been established.

Cat Data

The recommended daily therapeutic dose range for clindamycin hydrochloride (ClindaCure) is 11 to 33 mg/kg/day (5 to 15 mg/lb/day) depending on the severity of the condition. Clindamycin hydrochloride (ClindaCure) was tolerated with little evidence of toxicity in domestic shorthair cats when administered orally at 10× the minimum recommended therapeutic daily dose (11 mg/kg; 5 mg/lb) for 15 days, and at doses up to 5× the minimum recommended therapeutic dose for 42 days. Gastrointestinal tract upset (soft feces to diarrhea) occurred in control and treated cats with emesis occurring at doses 3× or greater than the minimum recommended therapeutic dose (11mg/kg/day; 5 mg/lb/day). Lymphocytic inflammation of the gallbladder was noted in a greater number of treated cats at the 110 mg/kg/day dose level than for control cats. No other effects were noted. Safety in gestating queens or breeding male cats has not been established.

Indications

ClindaCure (for use in dogs and cats) is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below:

Dogs

Skin infections (wounds and abscesses) due to: coagulase positive staphylococci (Staphylococcus aureus or Staphylococcus intermedius). Deep wounds and abscesses due to Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium ecrophorum and Clostridium perfringens.

Dental infections due to Staphyloccus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium pefringens.

Osteomyelitis due to Staphylococcus aureus, Bacteroides fragilis, Prevotella melaninogenicus, Fusobacterium necrophorum and Clostridium perfringens.

Cats

Skin infections (wounds and abscesses) due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp. Deep wounds and infections due to Clostridium perfringens and Bacteroides fragilis.

Dental infections due to Staphylococcus aureus, Staphylococcus intermedius, Streptococcus spp., Clostridium perfringens and Bacteroides fragilis.

PRINCIPAL DISPLAY PANEL - 20 mL Carton

NDC 50989-495-09

ClindaCure™
clindamycin hydrochloride liquid

Equivalent to 25 mg/mL clindamycin

For Use in Animals Only

VEDCO

Caution: Federal
(USA) law restricts this
drug to use by or on the
order of a licensed veterinarian.

ANADA # 200-291, Approved by FDA

20 mL

ClindaCure 
clindamycin hydrochloride liquid
Product Information
Product Type PRESCRIPTION ANIMAL DRUG Item Code (Source) NDC:50989-495
Route of Administration ORAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
clindamycin hydrochloride (clindamycin) clindamycin hydrochloride 25 mg  in 1 mL
Inactive Ingredients
Ingredient Name Strength
alcohol  
Packaging
# Item Code Package Description
1 NDC:50989-495-09 1 BOTTLE, GLASS (BOTTLE) in 1 CARTON
1 20 mL in 1 BOTTLE, GLASS
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
ANADA ANADA200291 01/10/2011
Labeler - Vedco, Inc. (021634266)
Establishment
Name Address ID/FEI Operations
Virbac Bridgeton 808558100 MANUFACTURE, RELABEL, REPACK
Revised: 01/2011   Vedco, Inc.
(web3)